A comparison of reduced dose total body irradiation (TBI) and cyclophosphamide with fludarabine and melphalan reduced intensity conditioning in adults with acute lymphoblastic leukaemia (ALL) in complete remission

Study design/Summary: This is a 2 arm, phase II, multicentre, randomised clinical trial in adult patients with Acute Lymphoblastic Leukaemia (ALL) in complete remission (CR) undergoing a allogeneic stem cell transplant (SCT) comparing the novel conditioning regimen of TBI and cyclophosphamide with the standard conditioning of fludarabine/melphalan/alemtuzumab (FMA)

Objectives: The primary objectives of this study are to compare the disease free survival at two years of patients with ALL after a TBI and cyclophosphamide stem cell transplant with that of patients transplanted using the FMA conditioning regimen. There are also other objectives in addition to the primary one which include; overall survival; cumulative incidence of disease relapse, non-relapse mortality; incidence of grade 2-4 acute graft-versus-host-disease (GvHD), incidence of chronic GvHD of any grade, occurrence and severity of veno-occlusive disease (VOD); duration of hospitalisation in the first year; quality of file, full donor chimerism at day 100 and TBI related symptomatic pulmonary toxicity following allogenic SCT.

Centres: 22 IMPACT centres

Target number of patients: 247 patients

Patient population: Patients with ALL who are suitable to undergo an allogenic SCT

Sponsorship/Funding: University of Birmingham, funded by the IMPACT network

Trial Status: Open to recruitment

Trial Contacts:

Start date: 17 September 2018

Duration: 7 years

If you are a patient and interested in taking part in a clinical trial, please speak with your consultant who will be able to offer you further information and discuss whether it is suitable for you. A referral from your medical team would be required in order to consider you for treatment on a clinical trial.